KPV: Gut Inflammation Research, Mostly in Rodents

TL;DR

KPV is a tiny three-amino-acid fragment cut from the same hormone (alpha-MSH) that controls tanning, but this fragment seems to fight inflammation without needing the tanning receptor at all. Nearly all of the research is in mice with induced colitis or in gut cells in a dish, aimed at inflammatory bowel disease and skin inflammation. There are no completed human trials, so any claim about how it works in a person is extrapolated from rodent and cell data, not proven in humans.

What is KPV?

KPV is a tripeptide (lysine-proline-valine) corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), a pro-opiomelanocortin (POMC)-derived peptide. Unlike full-length alpha-MSH, KPV does not require binding to the classical melanocortin receptors (MC1R-MC5R) to exert anti-inflammatory effects in several published preclinical models, which has made it a subject of interest as a possible "receptor-independent" fragment of the melanocortin anti-inflammatory pathway. Research on KPV has concentrated heavily on gastrointestinal inflammation and inflammatory bowel disease (IBD) models, as well as on skin inflammation. Most published evidence comes from cell culture and rodent colitis models rather than human clinical trials. This guide is for educational and research purposes only. Not medical advice.

How strong is the evidence?

Evidence Type	Status
Human RCT	✗
Observational	✗
Animal Studies	✔
In Vitro	✔
Regulatory Approval	✗

How does KPV work?

KPV's anti-inflammatory activity has been studied largely independent of the canonical melanocortin receptor pathway, distinguishing it from full-length alpha-MSH and other melanocortin peptides such as afamelanotide or bremelanotide. In cell culture and colonic epithelial models, KPV has been reported to inhibit activation of the pro-inflammatory transcription factor NF-κB, reducing downstream production of cytokines such as TNF-alpha, IL-1beta, IL-6, and IL-8, and interleukin-8-driven neutrophil chemotaxis. Researchers led by Dalmasso G and colleagues, among others, have investigated KPV's ability to be taken up by colonic epithelial cells via the PepT1 peptide transporter and to subsequently modulate intracellular inflammatory signalling, including effects on the NF-κB and MAPK pathways. Because KPV appears to act through mechanisms that do not strictly require melanocortin receptor engagement, it is studied as a candidate for isolating the anti-inflammatory component of the melanocortin system from its pigmentary and other receptor-mediated effects.

What has KPV been studied for?

Inflammatory Bowel Disease Models

The bulk of KPV research uses rodent models of colitis (commonly dextran sodium sulfate, DSS-induced colitis) to assess whether KPV reduces markers of intestinal inflammation, colonic tissue damage, and disease activity indices. Oral and rectal administration routes, including nanoparticle- and polymer-encapsulated delivery systems designed for colonic targeting, have been explored to improve local bioavailability.

Epithelial Barrier and Gut Signalling

Research has examined KPV's uptake into intestinal epithelial cells via the PepT1 transporter and its downstream effects on cytokine production and NF-κB activation within the gut epithelium, an area of interest for understanding localized anti-inflammatory peptide action in the digestive tract.

Skin Inflammation Models

Given its origin as an alpha-MSH fragment, and alpha-MSH's known role in skin immune modulation, KPV has been studied in topical and in vitro skin inflammation models for potential anti-inflammatory effects on keratinocytes and inflammatory skin conditions.

Melanocortin-Independent Anti-Inflammatory Signalling

A specific line of research has focused on demonstrating that KPV's anti-inflammatory action can occur in MC1R-deficient cell models, supporting the hypothesis of a receptor-independent or alternative-receptor mechanism distinct from classical melanocortin signalling.

What did the studies actually find?

Study / Model	Reported Effect
DSS-Induced Colitis Model, Mouse (Dalmasso G et al.)	Reported reduction in colonic inflammation markers and improved disease activity index scores with KPV administration versus control.
Colonic Epithelial Cell Culture (In vitro)	Reported inhibition of NF-κB activation and reduced pro-inflammatory cytokine (TNF-alpha, IL-8) secretion following KPV exposure.
Nanoparticle-Encapsulated KPV, Rodent Colitis Model	Reported improved localized delivery and comparable or enhanced anti-inflammatory effect versus free KPV in some formulations.
MC1R-Deficient Cell Models	Reported retained anti-inflammatory signalling activity, supporting a proposed receptor-independent mechanism.

What side effects were reported?

• No consistent adverse effects reported in published animal model literature at studied doses
• No human trial safety data available, as no completed human RCTs have been published
• Delivery-related effects (e.g., mild local irritation) reported with some experimental formulation routes rather than the peptide itself

Because KPV has not progressed to published human clinical trials, its safety profile in humans is not established. All available toxicity and tolerability data are derived from preclinical cell and animal studies, which should not be extrapolated directly to human use.

KPV at a glance

CAS Number

25696-59-3

Molecular Formula

C₁₆H₃₀N₄O₄

Molecular Weight

Approximately 342.4 g/mol

Half-Life

Very short (minutes) as a free tripeptide; a key driver of research into encapsulated/targeted delivery systems

Synonyms

Lysine-Proline-Valine, alpha-MSH(11-13), Alpha-MSH C-terminal tripeptide fragment

Research Classification

Melanocortin-derived tripeptide, Proposed receptor-independent anti-inflammatory peptide

The research this page cites

• Dalmasso G et al. 2011 — The PepT1-NOD2 signaling pathway aggravates induced colitis in mice. — Gastroenterology — [Animal / In vitro]
• Dalmasso G et al. 2008 — PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. — Gastroenterology — [Research paper]
• Kannengiesser K et al. 2008 — Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. — Inflammatory Bowel Diseases — [Animal]
• Catania A et al. 2004 — Targeting melanocortin receptors as a novel strategy to control inflammation. — Pharmacological Reviews — [Review / Mechanistic]

Note on the research base: Published literature on KPV consists almost entirely of preclinical animal and in vitro studies. No completed peer-reviewed human clinical trial data for KPV has been identified in the available scientific literature at the time of writing. Claims about human efficacy or safety should be treated as unestablished.

*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*